The second stage is now set in an epic legal question over a weighty and emotional matter of public policy: Whether patents connected to naturally occurring genes can be granted by the federal government. For Myriad Genetics, a lawsuit over its patents that concern two human genes related to ... [More]

On Tuesday, June 9, 2010, several plaintiffs, including a breast cancer patient and a cancer advocacy group, sued in a Sydney, Australia federal court to invalidate Myriad Genetics’ patents on the breast cancer susceptibility genes BRCA-1 and 2. According to published reports and comment... [More]

Just over two months ago, in a widely publicized decision we characterized as “a nearly complete victory for the plaintiffs and their supporters,” a district court judge in New York invalidated a number of Myriad Genetics’ patent claims, including the company’s paten... [More]

A landmark court case is set to challenge the legality of an Australian-issued patent for a breast and ovarian cancer gene. If successful, the case could set a precedent leading to other gene patents being overturned. The case could also strengthen calls by researchers, doctors and heal... [More]